| Recruiting | Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential NCT06326008 | Beijing GoBroad Hospital | Phase 1 |
| Not Yet Recruiting | A Study of Inotuzumab and Blinatumomab in People With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia NCT07313852 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia NCT07429461 | Zhejiang University | EARLY_Phase 1 |
| Recruiting | A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensi NCT07153796 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Par NCT07422337 | Arkansas Children's Hospital Research Institute | — |
| Recruiting | A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia NCT07223021 | Memorial Sloan Kettering Cancer Center | Phase 3 |
| Not Yet Recruiting | A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblasti NCT07043218 | Shanghai Tongji Hospital, Tongji University School of Medicine | Phase 1 |
| Withdrawn | A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) NCT06009107 | Juventas Cell Therapy Ltd. | Phase 1 / Phase 2 |
| Recruiting | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579 | Vironexis Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL NCT06863259 | Children's Hospital Medical Center, Cincinnati | Phase 1 |
| Recruiting | Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell NCT06879340 | University of Kansas Medical Center | Phase 1 |
| Recruiting | Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia NCT06793241 | Zhejiang University | EARLY_Phase 1 |
| Recruiting | CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies NCT06208735 | British Columbia Cancer Agency | Phase 1 |
| Recruiting | Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for NCT06581081 | Peking University People's Hospital | N/A |
| Recruiting | CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189 | University of Colorado, Denver | Phase 1 |
| Recruiting | Study of YK012 in B-cell Acute Lymphoblastic Leukemia NCT06580301 | Excyte Biopharma Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia NCT06559644 | The First Affiliated Hospital of Soochow University | EARLY_Phase 1 |
| Recruiting | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or NCT06395103 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Recruiting | Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescen NCT06608732 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia NCT06450067 | Juventas Cell Therapy Ltd. | — |
| Recruiting | CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With NCT06389305 | Beijing GoBroad Hospital | N/A |
| Recruiting | Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL NCT06080191 | Bambino Gesù Hospital and Research Institute | Phase 1 |
| Recruiting | Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL NCT06393985 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL P NCT06343090 | Beijing GoBroad Hospital | N/A |
| Recruiting | Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL NCT06507514 | The First Affiliated Hospital of Soochow University | Phase 1 |
| Recruiting | QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia NCT06056752 | Anhui Provincial Hospital | Phase 1 |
| Recruiting | Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies NCT06034275 | Vincerx Pharma, Inc. | Phase 1 |
| Completed | CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia NCT06027957 | Vinmec Research Institute of Stem Cell and Gene Technology | Phase 1 |
| Unknown | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinica NCT05747157 | Anhui Provincial Hospital | EARLY_Phase 1 |
| Recruiting | A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) NCT05667506 | Juventas Cell Therapy Ltd. | Phase 1 / Phase 2 |
| Recruiting | Co-administration of CART22-65s and huCART19 for B-ALL NCT05674175 | Stephan Grupp MD PhD | Phase 1 / Phase 2 |
| Unknown | Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL NCT05639179 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Phase 1 / Phase 2 |
| Withdrawn | CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma NCT05613348 | Zhujiang Hospital | Phase 1 / Phase 2 |
| Unknown | To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B- NCT05651191 | Hrain Biotechnology Co., Ltd. | EARLY_Phase 1 |
| Withdrawn | Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL NCT05571540 | Kunming Hope of Health Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL NCT03962465 | University of Virginia | Phase 1 |
| Active Not Recruiting | A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lympho NCT05460533 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lym NCT05648019 | KK Women's and Children's Hospital | Phase 2 |
| Recruiting | Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL NCT05082519 | Etan Orgel | Phase 2 |
| Unknown | NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL NCT05262673 | Shenzhen Geno-Immune Medical Institute | Phase 1 |
| Recruiting | Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukem NCT05210907 | Seoul National University Hospital | Phase 1 |
| Unknown | Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL NCT05559450 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Active Not Recruiting | Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies NCT06220097 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemi NCT06081478 | Beijing Tongren Hospital | Phase 2 |
| Withdrawn | Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL NCT04448834 | Dorothy Sipkins, MD, PhD | Phase 2 |
| Withdrawn | Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL NCT04156659 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | Natural Killer (NK) Cell Therapy for B-Cell Malignancies NCT05379647 | Zhejiang University | Phase 1 |
| Active Not Recruiting | Venetoclax Plus Inotuzumab for B-ALL NCT05016947 | Dana-Farber Cancer Institute | Phase 1 |
| Active Not Recruiting | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell NCT05020678 | Nkarta, Inc. | Phase 1 |
| Not Yet Recruiting | A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL NCT04595162 | Peking University Third Hospital | Phase 1 |
| Recruiting | UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL NCT04544592 | University of Colorado, Denver | Phase 1 / Phase 2 |
| Terminated | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies NCT04844086 | Eden BioCell Ltd. | Phase 1 |
| Recruiting | Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT NCT04746209 | Medical College of Wisconsin | Phase 2 |
| Unknown | Induced-T Cell Like NK Cells for B Cell Malignancies NCT04747093 | Nanfang Hospital, Southern Medical University | Phase 1 / Phase 2 |
| Completed | CAR T Cell Therapy Related Cardiovascular Outcomes NCT05130489 | University College London Hospitals | — |
| Terminated | Blinatumomab Bridging Therapy for BALL NCT04556084 | Michael Burke | Phase 2 |
| Recruiting | Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma NCT05333302 | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | Phase 1 |
| Unknown | Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies NCT04264039 | Xinqiao Hospital of Chongqing | EARLY_Phase 1 |
| Unknown | Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acut NCT04289220 | Yan'an Affiliated Hospital of Kunming Medical University | Phase 1 |
| Recruiting | CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL NCT05470777 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | Study of Out of Specification for Tisagenlecleucel NCT04094311 | Novartis Pharmaceuticals | Phase 3 |
| Unknown | A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL NCT04129099 | Hebei Yanda Ludaopei Hospital | EARLY_Phase 1 |
| Recruiting | Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia ( NCT04150497 | Cellectis S.A. | Phase 1 / Phase 2 |
| Unknown | Treatment of Hematological Malignancy With Novel CAR-T Cells. NCT04191941 | Timmune Biotech Inc. | EARLY_Phase 1 |
| Active Not Recruiting | Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients NCT03876769 | Novartis Pharmaceuticals | Phase 2 |
| Withdrawn | Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab NCT03982992 | Ludwig-Maximilians - University of Munich | Phase 2 |
| Unknown | Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-AL NCT04534634 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refra NCT03666000 | Imugene Limited | Phase 1 |
| Completed | A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL NCT03825718 | Hebei Yanda Ludaopei Hospital | EARLY_Phase 1 |
| Unknown | A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL NCT03825731 | Hebei Yanda Ludaopei Hospital | EARLY_Phase 1 |
| Unknown | CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. NCT03671460 | Tianjin Mycure Medical Technology Co., Ltd | Phase 1 |
| Recruiting | The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and You NCT03509961 | Pediatric Transplantation & Cellular Therapy Consortium | Phase 2 |
| Unknown | CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia NCT03854994 | Yan'an Affiliated Hospital of Kunming Medical University | Phase 1 |
| Recruiting | ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML NCT03595917 | Marlise Luskin, MD | Phase 1 |
| Unknown | CD19-CAR-T Cells in Patients With R/R B-ALL NCT03574168 | Bioceltech Therapeutics, Ltd. | Phase 1 |
| Unknown | CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL NCT03467256 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 1 / Phase 2 |
| Unknown | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies NCT03638206 | Shenzhen BinDeBio Ltd. | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Ly NCT03281551 | Pinze Lifetechnology Co. Ltd. | Phase 1 |
| Completed | CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) NCT03289455 | Autolus Limited | Phase 1 / Phase 2 |
| Unknown | Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk NCT03000335 | Curewize Health Ltd. | — |
| Completed | Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leuka NCT02746952 | Institut de Recherches Internationales Servier | Phase 1 |
| Completed | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Mali NCT02730312 | Xencor, Inc. | Phase 1 |
| Unknown | The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). NCT02924753 | Henan Cancer Hospital | Phase 1 |
| Withdrawn | Study of Efficacy and Safety of CTL019 in Adult ALL Patients NCT02167360 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients NCT02435849 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients NCT02228096 | Novartis Pharmaceuticals | Phase 2 |
| Suspended | Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leuke NCT01974479 | National University Health System, Singapore | Phase 1 |
| Completed | Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor A NCT01207388 | Amgen Research (Munich) GmbH | Phase 2 |
| Completed | Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia NCT00289562 | BioCryst Pharmaceuticals | Phase 1 / Phase 2 |